The verdict
Our read at a glance.
Whether palopegteriparatide is understood as steady, once-daily PTH replacement for hypoparathyroidism, distinct from the intermittent PTH used to build bone in osteoporosis, with the calcium balancing that replacement requires.
- The signal
- A randomized phase 3 trial (PaTHway) showed palopegteriparatide normalized blood calcium and let most people with chronic hypoparathyroidism stop or greatly cut conventional calcium and active vitamin D therapy, with the effect sustained over follow-up.
- The unknown
- Its long-term effects on bone, kidneys, and quality of life, how it compares with other PTH-replacement approaches, and the best way to titrate it to keep calcium in range.
- Our read
- A genuine advance for a neglected disease: steady, once-daily PTH replacement that can finally normalize calcium in hypoparathyroidism and free people from heavy supplement regimens. The key distinction is continuous PTH for replacement here, versus the brief daily pulse of teriparatide used to build bone in osteoporosis. It is a specialist hormone-replacement drug needing calcium monitoring, not a general bone or wellness treatment.
The mechanism
How it works.
Parathyroid hormone (PTH) keeps blood calcium in range; in hypoparathyroidism the parathyroid glands don't make enough, so calcium runs low. Plain PTH disappears from the blood within minutes, and giving it as a once-daily spike (as the osteoporosis drug teriparatide does) builds bone but doesn't hold calcium steady. Palopegteriparatide is a 'prodrug': PTH(1-34) attached to a carrier that releases it slowly, so a single daily injection trickles out PTH over the whole day. That steady, near-physiologic level restores normal calcium handling, the way working parathyroid glands would, which is why it can replace the missing hormone rather than just pulse it. The same hormone, delivered continuously instead of in spikes, is what makes it a replacement therapy rather than a bone-builder.
Safety & regulatory boundary
The consequential part.
Because it replaces a calcium-controlling hormone, doses must be carefully adjusted and calcium monitored to avoid levels that are too high or too low; injection-site reactions and headache occur. It is approved specifically for hypoparathyroidism, not for osteoporosis (where the intermittent PTH drug teriparatide is used) or general bone or 'hormone optimization' use. Yorvipath is a specialist-prescribed daily injection, distinct from teriparatide, abaloparatide, and the older full-length PTH product.
What's next
What we're watching.
Long-term bone and kidney outcomes, durability of calcium control, comparisons with other PTH-replacement strategies, and real-world titration experience.
Context
Why this is discussed.
Hypoparathyroidism leaves people short of parathyroid hormone, so they struggle with low calcium and lean on large doses of calcium and active vitamin D that don't fully fix the problem and can harm the kidneys. Palopegteriparatide actually replaces the missing hormone in a steady, near-natural way, which can restore normal calcium and reduce or remove the need for those supplements.
The evidence base
13 cited references.
Regulatory & labels1
Ascendis Pharma, Endocrinology, Inc. (FDA label) · 2026
Registered trials3
ClinicalTrials.gov · PHASE3 · RECRUITING · 2026-04-16
ClinicalTrials.gov · PHASE3 · COMPLETED · 2021-02-16
ClinicalTrials.gov · COMPLETED · 2024-06-01
Indexed literature (PubMed)9
Clarke BL et al. · J Clin Endocrinol Metab · 2025
Khan AA et al. · J Bone Miner Res · 2023
Khan S et al. · Nat Rev Endocrinol · 2025
Bonnet AL et al. · J Bone Miner Res · 2025
Khan AA et al. · J Clin Endocrinol Metab · 2022
Rejnmark L et al. · Adv Ther · 2024
Palermo A et al. · Curr Osteoporos Rep · 2025
Rejnmark L · Endocrinol Metab (Seoul) · 2024
Graham T et al. · Endocr Pract · 2025
Keep reading